Table 4.
Questions/Priority area | Methodology considerations |
---|---|
Heterogeneity in how stress/allostatic load paradigms and indices of adaptation/resilience are defined. | Consensus determined consistent definitions and measurements across multiple domains. Movement from efficacy to effectiveness. research from small samples to populations. |
Lack of standardization of MBTs across studies and mediators of their positive effects (e.g., physiologic, biochemical, brain and body organ level, immune, microbiome, epigenetic, psychological, behavioral). | Determination and standardization of “active” components of MBTs. Consistent domains of biological and psychological outcomes and mediators. Understanding of processes and interrelationships at multiple levels: genes, cells, organs, networks, and organism. |
Differentiation of short-term and long-term outcomes in stress reduction and increased resilience and differentiating response from remission and relapse prevention. | More longitudinal studies. Machine learning analysis of trial results to define novel biomarkers or mechanisms. |
Better incorporation of health-technologies to increase access to MBTs, scalability, and predictive capacity to identify at-risk populations to move from treatment to prevention. | Evaluation of effectiveness of technology-enhanced behavioral interventions. Machine-learning for better predictive analytics to personalize interventions. |